Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy

Clinical and Experimental Rheumatology

Volumn 26, Issue 1, 2008, Pages 45-51

  Favalli, Ennio Giulio ^a,c   Marchesoni, Antonio ^a   Colombo, Giorgio Lorenzo ^b   Sinigaglia, Luigi ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b SAVE Studi Analisi Valutazioni Economiche   (Italy)

^c NONE   (Italy)

Author keywords

Anti TNF ; Cost; Dose; Infliximab; Rheumatoid arthritis; Treatment; Vial

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

ADULT; ARTICLE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INFUSION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; ITALY; LEGIONNAIRE DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 40849113561     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552-63.
2. LIPSKY PE, VAN DER HEIJDE DMFM, ST. CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
3. ST. CLAIR EW: Radiographic joint damAge in rheumatoid arthritis: a community-based perspective. Arthritis Rheum 2001; 44: 1231-3.
4. MAINI R, ST. CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
5. ST. CLAIR EW, WAGNER CL, FASANMADE AA et al.: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9.
6. DUREZ P, VAN DEN BOSCH F, CORLUY L et al.: A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: A Belgian prospective study. Rheumatology 2005; 44: 465-8.
7. EDREES AF, MISRA SN, ABDOU NI: Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005; 23: 469-74.
8. VAN VOLLENHOVEN RE, BRANNEMARK S, KLARESKOG L: Dose escalation of infliximab in clinical practice: Improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004; 63: 426-30.
9. ITALIAN SOCIETY OF RHEUMATOLOGY: ANTARES Project. Available at: http://www.reumatologia.it
10. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
11. PREVOO ML, VAN'T HOF MA, KUPER HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
12. VAN GESTEL AM, HAAGSMA CJ, VAN RIEL PL et al.: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1999; 41: 1845-50.
13. SIDEROPOULOS P, BERTSIAS G, KRITIKOS HD et al.: Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: Dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 2004; 63: 144-8.
14. DEN BROEDER AA, CREEMERS MCW, VAN GESTEL AM et al.: Dose titration using the Disease Activity Score (DAS 28) in rheumatoid arthritis patients treated with anti-TNF-α. Rheumatology 2002; 41: 638-42.
15. COLOMBO GL, MUZIO A, LONGHI A: Valutazione economica di infliximab (Remicade®) vs etanercept (Enbrel®) nel trattamento dell'artrite reumatoide. Farmacoeconomia e Percorsi Terapeutici 2003; 4: 79-88.
16. AGARWAL SK, MAIER AL, CHIBNIK LB et al.: Pattern of infliximab utilization in rheumatoid arthritis patients at an Academic Medical Center. Arthritis Rheum 2005; 53: 872-78.
17. VAN VOLLENHOVEN RF, BRANNEMARK S, KLARESKOG: Dose escalation of infliximab in clinical practice: Improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004; 63: 426-30.
18. GEORGE D, KADLUBECK P, BATRA D, GOLDBERG G: Infliximab dose and charge escalation patterns in managed care. Manag Care Interface 2004 (Suppl. A): 5-8.
19. ETEMAD L, YU EB, WANKE LA: Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005; 18: 21-7.
20. BERGER A, EDELSBERG J, LI TT et al.: Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005; 39: 2021-5.
21. STERN R, WOLFE F: Infliximab doRe and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1538-45.
22. ARIZA-ARIZA R, NAVARRO-SARABIA F, HERNÁNDEZ-CRUZ B et al.: Dose escalation of anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46: 529-32.
23. WEYCKER D, YU EB, WOLLEY JM et al.: Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged ≥ 65 years with rheumatoid arthritis. Clin Therap 2005; 27: 646-56.
24. GILBERT TD, SMITH D, OLLENDORF DA: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: A retrospective cohort study. BMC Muscoloskeletal Disord 2004; 5: 36.
25. OLLENDORF DA, MASSAROTTI E, BIRBARA C et al.: Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005; 11: 383-93.
26. SOMERVILLE M, BROOKSBY A, SCOTT DGI: Maximizing the use of scarce resources: Vial optimization. Rheumatology 2006; 45: 354-5.